Abstract
Mood disorders place substantial clinical, social and economic burdens on individuals with the disorders, as well as on their families and wider society. At the same time, the scarcity of healthcare resources necessitates the efficiency of alternative treatments to be examined. Economic evaluations of the seemingly expensive SSRIs have tended to suggest that they are cost-effective compared with tricyclics due to better clinical outcomes and reduced hospitalizations. However, a third generation of antidepressants may bring new cost concerns. The high cost of psychological therapies may mean that they are only cost-effective for particular sub-groups of patients, as suggested by recent NICE guidelines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
